Cohance Lifesciences Ltd
Cohance Lifesciences Ltd (COHANCE) last reported results for the quarter ended Jun 2026, with sales of ₹422 crore and net profit of ₹-45 crore. The stock last traded at ₹453, a market capitalisation of ₹17,328 crore, on a P/E of 161. Over the past 52 weeks the stock has ranged between ₹267 and ₹918. Figures are as of 6 Oct 2026 and are not real time.
Cohance Lifesciences Ltd share price and key metrics
- Current price
- ₹453
- Market cap
- ₹17,328 cr
- Stock P/E
- 161
- Book value
- ₹102
- ROE
- 4.89%
- ROCE
- 5.81%
- Dividend yield
- 0.00%
- 52w high / low
- 918/267
Metrics as of 6 Oct 2026. Not real time.
Track Cohance Lifesciences Ltd
Cruxal reads every Cohance Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cohance Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 19%
- TTM
- -20%
- 10 Years
- %
- 5 Years
- -12%
- 3 Years
- -23%
- TTM
- -77%
- 10 Years
- %
- 5 Years
- -4%
- 3 Years
- -8%
- 1 Year
- -49%
- 10 Years
- %
- 5 Years
- 15%
- 3 Years
- 11%
- Last Year
- 5%
Cohance Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹422 cr, down 23.1% from ₹549 cr a year earlier. Net profit swung to a loss of ₹45 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 604 | 676 | 840 | 549 | 556 | 545 | 619 | 422 |
| Expenses | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 |
| Operating profit | 205 | 237 | 229 | 112 | 121 | 95 | 99 | 1 |
| OPM % | 34% | 35% | 27% | 20% | 22% | 18% | 16% | 0.3% |
| Other income | 16 | 22 | -4 | 6 | 16 | 1 | -18 | 12 |
| Interest | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 |
| Profit before tax | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 |
| Tax % | 21% | 25% | 27% | 26% | 21% | 29% | 58% | 5% |
| Net profit | 138 | 153 | 117 | 46 | 66 | 29 | 8 | -45 |
| EPS (₹) | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Cohance Lifesciences Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 2,608 | 2,269 | 2,142 |
| Operating profit | 172 | 385 | 443 | 582 | 574 | 406 | 797 | 427 | 316 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 19% | 15% |
| Net profit | 109 | 317 | 362 | 454 | 411 | 300 | 484 | 150 | 59 |
| EPS (₹) | — | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 19.14 | 4.68 | 2.78 |
TTM is the trailing twelve months to the most recent quarter.
Cohance Lifesciences Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.00 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 3,623 | 3,873 |
| Borrowings | 83 | 186 | 143 | 97 | 70 | 65 | 486 | 400 |
| Other liabilities | 123 | 142 | 151 | 205 | 160 | 138 | 1,346 | 1,415 |
| Total liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 5,480 | 5,727 |
| Fixed assets | 271 | 357 | 441 | 534 | 663 | 670 | 3,107 | 3,369 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 334 | 178 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 529 |
| Other assets | 394 | 376 | 395 | 667 | 601 | 501 | 1,702 | 1,652 |
| Total assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 5,480 | 5,727 |
As reported by the company. Total assets equal total liabilities by construction.
Cohance Lifesciences Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 50 | 407 | 383 | 330 | 457 | 358 | 673 | 368 |
| Cash from investing | -65 | -413 | -311 | -136 | -195 | -362 | -388 | -251 |
| Cash from financing | 26 | 7 | -76 | -156 | -242 | -14 | -327 | -165 |
| Net cash flow | 11 | 1 | -5 | 37 | 20 | -18 | -42 | -48 |
| Free cash flow | -6 | 304 | 272 | 255 | 171 | 307 | 357 | 169 |
| CFO / operating profit | 49% | 128% | 111% | 88% | 105% | 115% | 107% | 102% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Cohance Lifesciences Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 50% | 40% | 41% | 32% | 19% | 21% | 6% |
| Debtor days | 142 | 51 | 37 | 65 | 30 | 46 | 108 | 110 |
| Inventory days | 556 | 278 | 243 | 259 | 279 | 268 | 209 | 310 |
| Days payable | 190 | 113 | 100 | 97 | 63 | 49 | 120 | 157 |
| Cash conversion cycle | 509 | 217 | 180 | 228 | 247 | 265 | 197 | 263 |
| Working capital days | 205 | 64 | 56 | 108 | 99 | 115 | 106 | 133 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Cohance Lifesciences Ltd shareholding pattern
Promoters held 57.49% at Jun 2026, down from 66.41% at Jun 2025. FIIs 6.50% and DIIs 20.09%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.10% | 50.10% | 50.10% | 66.41% | 57.49% | 57.49% | 57.49% | 57.49% |
| FIIs | 10.70% | 10.84% | 11.05% | 7.23% | 6.51% | 6.01% | 5.59% | 6.50% |
| DIIs | 16.95% | 16.67% | 16.60% | 11.40% | 20.81% | 21.57% | 21.79% | 20.09% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 22.26% | 22.37% | 22.24% | 14.95% | 15.16% | 14.91% | 15.11% | 15.92% |
| No. of shareholders | 69,337 | 84,210 | 86,325 | 80,910 | 75,284 | 81,877 | 85,230 | 99,149 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cohance Lifesciences Ltd corporate filings
- Cohance Lifesciences appoints Mr. Abhimanyu Ojha as CFO effective 12 October 2026, signaling strategic leadership transitionCompany Updatelow impact
Cruxal's analysis: Cohance Lifesciences has announced the appointment of Mr. Abhimanyu Ojha as Chief…
Read the full analysis - Compliance Certificate under 74(5) of SEBI (DP) Regulations 2018Company Updatelow impact
- Cohance Lifesciences Ltd receives ESG rating from Crisil ESG Ratings & Analytics LimitedCompany Updatelow impact
Cruxal's analysis: The company, with a market cap of approximately 17,328 crore and current stock price of…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Cohance Lifesciences Ltd issues general updateCompany Updatelow impact
Cruxal's analysis: The company has filed a general update with the stock exchange dated September 21, 2026…
Read the full analysis - Cohance Lifesciences Ltd issues general updateCompany Updatelow impact
Cruxal's analysis: Cohance Lifesciences has filed a general update with the exchange on September 18, 2026…
Read the full analysis - Cohance Lifesciences Limited concludes 8th Annual General Meeting with all resolutions passedAGM/EGMlow impact
Cruxal's analysis: Cohance Lifesciences Limited has successfully concluded its 8th Annual General Meeting…
Read the full analysis - Cohance Lifesciences Ltd schedules investor meet for September 17, 2026Company Updatelow impact
Cruxal's analysis: Cohance Lifesciences has issued an intimation regarding an analyst/investor meet…
Read the full analysis - Cohance Lifesciences Ltd announces completion of USFDA inspectionCompany Updatelow impact
Cruxal's analysis: The company has formally announced the completion of a USFDA inspection. No specific…
Read the full analysis - Cohance Lifesciences Ltd: Filing of routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: The company has filed a press release under Regulation 30 of the SEBI (LODR) Regulations…
Read the full analysis - Cohance Lifesciences to invest USD 18 million to consolidate control in NJ Bio and Aruka Bio to bolster ADC capabilitiesOthershigh impact
Cruxal's analysis: Cohance Lifesciences Limited has announced a strategic reorganization involving an…
Read the full analysis - Cohance Lifesciences Ltd schedules investor meeting for August 27, 2026Company Updatelow impact
Cruxal's analysis: Cohance Lifesciences has issued an intimation regarding an analyst/investor meeting…
Read the full analysis - Cohance Lifesciences Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: The company has fulfilled its statutory obligation under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Cohance Lifesciences Ltd files Business Responsibility and Sustainability Report (BRSR)Otherslow impact
Cruxal's analysis: Cohance Lifesciences has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Cohance Lifesciences Ltd releases Annual Report for FY 2026Otherslow impact
Cruxal's analysis: Cohance Lifesciences has filed its Annual Report for the financial year 2026. This is a…
Read the full analysis - Cohance Lifesciences Limited Announces 8th Annual General Meeting Scheduled for September 17, 2026AGM/EGMlow impact
Cruxal's analysis: Cohance Lifesciences Limited has issued a formal notice for its 8th Annual General…
Read the full analysis - Cohance Lifesciences Limited reports credit rating withdrawal by CRISIL following non-cooperationCompany Updatehigh impact
Cruxal's analysis: Cohance Lifesciences Limited has requested the withdrawal of its credit ratings from…
Read the full analysis - DSP Trustee Private Limited reduces stake in Cohance Lifesciences Limited by 0.76% via open market saleInsider Trading / SASTlow impact
Cruxal's analysis: Cohance Lifesciences Limited has seen a reduction in shareholding by DSP Trustee Private…
Read the full analysis - Cohance Lifesciences Q1 FY27 Earnings Call: Revenue Declines 23% YoY Amidst Operational Headwinds and USFDA InspectionCompany Updatehigh impact
Cruxal's analysis: Cohance Lifesciences reported a challenging Q1 FY27 with consolidated revenue of 422.3…
Read the full analysis - Cohance Lifesciences Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Cohance Lifesciences has published its financial results in newspapers as per Regulation…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.